UNSPSC 51361921: Talbutal

This classification denotes a barbiturate with the molecular formula C11H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4YIR8202AX, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-methypropyl)-5-(2-propenyl)- but generally known as talbutal, which bears US NIH Compound Identifier 8275. European Medicines Agency schedules Talbutal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10802MIG. The term TALBUTAL is an International Non-Proprietary Name.

UNSPSC 51361921 Talbutal (Commodity) covers pharmaceutical products and related health-care commodities that state and local governments procure for public health, emergency response, and community health programs. Recent opportunities show state and local buyers acquiring naloxone and drug deactivation systems for opioid-crisis response, generic pharmaceuticals and over-the-counter products through cooperative purchasing frameworks, and exploring direct-to-manufacturer prescription programs to improve cost management and supply-chain efficiency. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The code reflects procurement spanning emergency pharmaceuticals, chronic-disease and preventive-care medications, and operational pharmacy support across diverse public-health use cases.

Recent activity centers in the Upper Midwest and Southeast, with notable solicitations in Minnesota, Texas, and Florida. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026 and a two-year initial contract term; evaluation weighted heavily toward price competitiveness (75 percent), with vendors required to maintain cGMP and Drug Supply Chain Security Act compliance and carry professional liability coverage of $2 million. Seminole County, Florida issued an IFB in June 2026 (due July 26, 2023—note date inconsistency in source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. Texas Health and Human Services Commission posted a Request for Information in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling potential future procurement of pharmacy-benefit services outside traditional pharmacy-benefit-manager and group-purchasing-organization channels.